

CALENDAR

26 March – 1 April 2000

European School of Genetic Medicine Scientific Programme of the 13th Course in Medical Genetics Genova, Italy

Course programme:

26 March 2000 Introduction to Genetic Analysis

27 March 2000 Genetics of Complex Traits

28 March 2000 Molecular Genetics

29 March 2000 Clinical Genetics

30 March 2000 Neurogenetics

31 March 2000 Genome Projects

1 April 2000 Genetic Medicine in Year 2000

Further information from:

Alessandro Palmesino, European Genetics Foundation, Palazzo del Melograno, Piazza Campetto 2/8, 16123 Genova, Italy.

Tel: + 39 010 246 46 46, + 39 010 246 41 66; Fax: + 39 010 246 60 55; E-mail: eurgef@tin.it; Website: <http://www.eurogene.org>

5–9 April 2000

Eurogin 2000

Global Challenge of Cervical Cancer Prevention 4th International Multidisciplinary Congress Paris, France

Further information from:

Congress Secretariat, BAXON, N. Duraincie, C Boussin, 220–224 boulevard Jean, Jaures, 92773 Boulogne Cedex, France.

Tel: + 33 (0) 15520 23 83; Fax: + 33 (0) 1552023 93;

E-mail: duraincie.baxon@covos.fr

27 September – 1 October 2000

Pigment Cell research – Perspectives for the Third Millennium

University of Ulm/Donau, Germany

Further information from:

Department of Dermatology, University of Ulm, ESPCR 2000, 89070 Ulm/Donau, Germany. Tel: + 49 (0) 731 50 22251;

Fax: + 49 (0) 731 50 23772; E-mail: ralf.peter@medizin.uni-ulm.de;

Website: <http://www.uni-ulm.de/klinik/dermatologie>

10–13 July 2000

29th British Congress of Obstetrics and Gynaecology International Convention Centre

Birmingham, UK

Further information:

BCOG Secretariat, Congress House, 65 West Drive, Cheam, Sutton, Surrey SM2 7NB, UK. Tel: + 44 (0) 20 8661 0877;

Fax: + 44 (0) 20 8661 9036; E-mail: info@conforg.com

Errata

Br J Cancer 80(11): 1689–1696

Fractionated γ -irradiation renders tumour cells more responsive to apoptotic signals through CD95

MA Sheard, PH Krammer and J Zaloudik

Figure 2A was reconfigured during the editorial process from vertical columns to horizontal rows, inadvertently rendering the text inconsistent with the layout of the Figure. References in the text to the ‘top panels’ of Figure 2A should be read as ‘left panels’, and ‘bottom panels’ should be read as ‘right panels’.

Br J Cancer 81(5): 835–840

Chemotherapy for unresectable and recurrent intramedullary glial tumours in children

V Doireau, J Grill, M Zerah, A Lellouch-Tubiana, D Couanet, P Chastagner, JC Marchal, Y Grignon, Z Chouffai and C Kalifa for the Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP)

There was an error in the conversion of the doses of procarbazine from mg kg⁻¹ to mg m⁻². The dose in mg kg⁻¹ is correct, i.e. 4 mg kg⁻¹ but the dose in mg m⁻² should be 120 mg m⁻² and not 200 mg m⁻² as mentioned in the paper. To summarize, the doses of chemotherapy to be used in this protocol are:

CARBOPLATIN	15 mg kg ⁻¹ or 450 mg m ⁻² on DAY 1
PROCARBAZINE	4 mg kg ⁻¹ or 120 mg m ⁻² on DAY 1 TO DAY 7
ETOPOSIDE	5 mg kg ⁻¹ or 150 mg m ⁻² on DAY 22 AND DAY 23
CISPLATIN	1 mg kg ⁻¹ or 30 mg m ⁻² on DAY 22 AND DAY 23
VINCRIStINE	0.05 mg kg ⁻¹ or 1.5 mg m ⁻² on DAY 43
CYCLOPHOSPHAMIDE	50 mg kg ⁻¹ or 1500 mg m ⁻² on DAY 43.

For further information concerning the modalities of drug administration, the readers are invited to contact the authors at the address indicated in the paper.